Jefferies Financial Group Equities Analysts Raise Earnings Estimates for Atara Biotherapeutics Inc (NASDAQ:ATRA)

Atara Biotherapeutics Inc (NASDAQ:ATRA) – Stock analysts at Jefferies Financial Group raised their FY2019 earnings estimates for Atara Biotherapeutics in a report released on Sunday, November 10th. Jefferies Financial Group analyst M. Raycroft now forecasts that the biotechnology company will earn ($5.63) per share for the year, up from their prior estimate of ($5.77). Jefferies Financial Group has a “Hold” rating and a $15.00 price objective on the stock. Jefferies Financial Group also issued estimates for Atara Biotherapeutics’ Q4 2019 earnings at ($1.32) EPS, FY2020 earnings at ($3.09) EPS, FY2021 earnings at ($3.45) EPS, FY2022 earnings at ($2.22) EPS and FY2023 earnings at ($1.91) EPS.

Atara Biotherapeutics (NASDAQ:ATRA) last announced its quarterly earnings results on Thursday, November 7th. The biotechnology company reported ($1.31) EPS for the quarter, beating the Zacks’ consensus estimate of ($1.40) by $0.09.

Several other analysts also recently issued reports on the stock. Goldman Sachs Group downgraded shares of Atara Biotherapeutics from a “neutral” rating to a “sell” rating and decreased their price objective for the stock from $14.00 to $9.00 in a research note on Friday, September 27th. ValuEngine raised shares of Atara Biotherapeutics from a “hold” rating to a “buy” rating in a research note on Wednesday, October 2nd. Cowen reaffirmed a “buy” rating on shares of Atara Biotherapeutics in a research note on Friday, September 13th. JPMorgan Chase & Co. lowered shares of Atara Biotherapeutics from an “overweight” rating to a “neutral” rating and cut their price objective for the company from $43.00 to $22.00 in a report on Friday, November 8th. Finally, Stifel Nicolaus reissued a “buy” rating on shares of Atara Biotherapeutics in a report on Friday, October 25th. Two equities research analysts have rated the stock with a sell rating, three have assigned a hold rating and nine have assigned a buy rating to the company. The company currently has an average rating of “Buy” and an average target price of $28.22.

Shares of NASDAQ:ATRA opened at $13.10 on Wednesday. The company has a current ratio of 9.56, a quick ratio of 9.56 and a debt-to-equity ratio of 0.05. Atara Biotherapeutics has a 12 month low of $10.38 and a 12 month high of $43.94. The company has a 50-day moving average price of $12.97 and a 200 day moving average price of $17.77. The company has a market cap of $725.62 million, a price-to-earnings ratio of -2.49 and a beta of 2.04.

Several institutional investors and hedge funds have recently made changes to their positions in the company. Marshall Wace LLP bought a new stake in Atara Biotherapeutics in the first quarter worth about $284,000. Coronation Fund Managers Ltd. raised its stake in shares of Atara Biotherapeutics by 174.6% during the second quarter. Coronation Fund Managers Ltd. now owns 92,050 shares of the biotechnology company’s stock valued at $1,851,000 after acquiring an additional 58,530 shares in the last quarter. Aperio Group LLC bought a new stake in shares of Atara Biotherapeutics during the second quarter valued at approximately $63,000. Trellus Management Company LLC bought a new stake in shares of Atara Biotherapeutics during the second quarter valued at approximately $503,000. Finally, DekaBank Deutsche Girozentrale raised its stake in shares of Atara Biotherapeutics by 63.6% during the second quarter. DekaBank Deutsche Girozentrale now owns 14,400 shares of the biotechnology company’s stock valued at $292,000 after acquiring an additional 5,600 shares in the last quarter. 92.47% of the stock is currently owned by hedge funds and other institutional investors.

In other Atara Biotherapeutics news, insider Joe Newell sold 3,500 shares of Atara Biotherapeutics stock in a transaction on Friday, September 27th. The shares were sold at an average price of $13.51, for a total value of $47,285.00. Following the transaction, the insider now directly owns 57,998 shares of the company’s stock, valued at $783,552.98. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. 7.00% of the stock is currently owned by insiders.

About Atara Biotherapeutics

Atara Biotherapeutics, Inc, an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. It is developing tabelecleucel, a T-cell immunotherapy that is Phase III clinical trials for the treatment of rituximab-refractory epstein-barr virus (EBV) associated post-transplant lymphoproliferative disorder, as well as other EBV associated hematologic and solid tumors, including nasopharyngeal carcinoma.

Featured Story: Google Finance

Earnings History and Estimates for Atara Biotherapeutics (NASDAQ:ATRA)

Receive News & Ratings for Atara Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atara Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.